Funding For TB Prevention, Treatment, Research At All-Time High But Short Of Need, 2 Reports Say
CIDRAP News: Reports: Tuberculosis R&D funding still falling short
“Global funding for tuberculosis research and development (TB R&D) has reached an all-time high, but funding goals for efforts to eliminate the disease remain far out of reach, according to two reports released [Tuesday]. In an analysis of TB research funding trends from 2005 through 2018, the Treatment Action Group (TAG) found that global funding for TB R&D totaled $916 million US for fiscal year 2018, an increase of $134 million US from 2017. But the Stop TB Partnership’s (STBP’s) updated Global Plan to End TB calls for $2.6 billion US per year for R&D of new diagnostics, new drugs, and a new vaccine. That’s in addition to $13 billion US a year needed for TB prevention and care, the group says…” (Dall, 12/10).
The Telegraph: Up to $15bn a year needed to control TB as world urged to ‘mobilize’ against the disease
“…The [Stop TB] action plan also calls for increased uptake of new drugs specially formulated for children with the drug-resistant form of the disease. In the past children have had to take unpalatable adult versions of the drugs but new child-friendly treatments need to be urgently rolled out. … To stimulate an activist movement the plan also asks for $2.5 million to fund grassroots, community organizations — similar to grassroots HIV groups which have led effective campaigns for both new drugs and social change…” (Gulland, 12/10).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.